Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BPC-157 and LL-37 — mechanism, dosing, side effects, legal status, and pricing.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid peptide (starting with two leucines) cleaved from the hCAP-18 precursor. It has broad-spectrum antimicrobial activity and immunomodulatory roles, but is also implicated in the pathogenesis of autoimmune and inflammatory skin diseases including psoriasis, rosacea, and lupus. Not FDA-approved; research-use only.
BPC-157
LL-37
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
BPC-157
LL-37
COA corpus from Disclosed Labs — independently tested batches only.
BPC-157
334
COAs
99.3%
Avg purity
16
Labs
LL-37
31
COAs
99.2%
Avg purity
8
Labs
BPC-157 is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. LL-37 remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage (PMID 21548867, 30915550). Preclinical tendon studies demonstrate enhanced growth hormone receptor expression in fibroblasts (PMID 25415472) and promote tendon outgrowth, cell survival, and cell migration (PMID 21030672). Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses (200–500 mcg) commonly used on the grey market, and pharmacokinetics and long-term safety in humans are not well characterized.
Key references
LL-37 was characterized in the mid-1990s as the processed antimicrobial product of hCAP-18 (Gudmundsson et al., 1996). Dürr et al. (2006, Biochim Biophys Acta, PMID 16716248) provided a foundational review of its structure and activity as the sole human cathelicidin. Overhage et al. (2008, Infection and Immunity, PMID 18591225) showed LL-37 prevents Pseudomonas aeruginosa biofilm formation at 0.5 µg/mL — far below its MIC. A randomized, placebo-controlled Phase 1/2 trial (Grönberg et al., 2014, Wound Repair and Regeneration, PMID 25041740) found topical LL-37 safely accelerated healing of hard-to-heal venous leg ulcers at low doses. Its dual role in autoimmunity is well established: Lande et al. (2014, Nature Communications, PMID 25470744) identified LL-37 as a T-cell autoantigen in two-thirds of moderate-to-severe plaque psoriasis patients. No FDA approval exists for any indication. Injectable grey-market protocols for Lyme, biofilm, or mold illness lack controlled clinical evidence and carry theoretical autoimmune risk given LL-37's role in psoriasis, lupus, and rosacea pathogenesis.
BPC-157 (Recovery) and LL-37 (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs